Study #2016-0713
A Phase I/II Study of SEL24 in Patients with Acute Myeloid Leukemia
MD Anderson Study Status
Enrolling
Treatment Agent
SEL24/MEN1703
Description
The purpose of the clinical trial is to identify the maximum tolerated dose of SEL24/MEN1703 and to further investigate its safety profile in patients with Acute Myeloid Leukemia.
Information and next steps
Disease:
Acute Myeloid Leukemia
Study phase:
I/II
Physician name:
Farhad Ravandi-Kashani
Department:
Leukemia
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Due to our response to COVID-19, all blood donations at MD Anderson
Blood Donor Center locations are being held by appointment only.